2021
A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1
Weiss SA, Djureinovic D, Jessel S, Krykbaeva I, Zhang L, Jilaveanu L, Ralabate A, Johnson B, Levit NS, Anderson G, Zelterman D, Wei W, Mahajan A, Trifan O, Bosenberg M, Kaech SM, Perry CJ, Damsky W, Gettinger S, Sznol M, Hurwitz M, Kluger HM. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non–Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1. Clinical Cancer Research 2021, 27: 4757-4767. PMID: 34140403, PMCID: PMC9236708, DOI: 10.1158/1078-0432.ccr-21-0903.Peer-Reviewed Original ResearchConceptsAnti-PD-1/PD-L1Non-small cell lung cancerCell lung cancerRenal cell carcinomaPD-L1Lung cancerDisease progressionCommon treatment-related adverse eventsPD-1/PD-L1 inhibitorsTreatment-related adverse eventsPhase 2 doseSubstantial clinical challengeUnconfirmed partial responseDose-limiting toxicityPD-L1 inhibitorsPhase I trialDose-escalation designPro-inflammatory cytokinesMultiple tumor typesAsymptomatic elevationStable diseaseIntolerable toxicityAdverse eventsMedian durationPartial response
2013
Beta prime regression with application to risky behavior frequency screening
Tulupyev A, Suvorova A, Sousa J, Zelterman D. Beta prime regression with application to risky behavior frequency screening. Statistics In Medicine 2013, 32: 4044-4056. PMID: 23616229, PMCID: PMC3789864, DOI: 10.1002/sim.5820.Peer-Reviewed Original Research
2012
The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer
Pilarski R, Patel DA, Weitzel J, McVeigh T, Dorairaj JJ, Heneghan HM, Miller N, Weidhaas JB, Kerin MJ, McKenna M, Wu X, Hildebrandt M, Zelterman D, Sand S, Shulman LP. The KRAS-Variant Is Associated with Risk of Developing Double Primary Breast and Ovarian Cancer. PLOS ONE 2012, 7: e37891. PMID: 22662244, PMCID: PMC3360659, DOI: 10.1371/journal.pone.0037891.Peer-Reviewed Original ResearchConceptsPrimary patientsOvarian cancer riskKRAS-variantOvarian cancer diagnosisOvarian cancerPrimary cancerFamily historyCancer diagnosisCancer riskTriple-negative breast cancerAdditional cancer diagnosesDouble primary breastTriple primary cancersPositive family historyAge of diagnosisNegative breast cancerDeleterious BRCA mutationsBreast primaryPathologic diagnosisBRCA mutationsPrimary breastBreast cancerHBOC familiesPatientsHereditary breast
2011
Fructosamine reference ranges in rhesus macaques (Macaca mulatta).
Williams-Fritze MJ, Smith PC, Zelterman D, Scholz JA. Fructosamine reference ranges in rhesus macaques (Macaca mulatta). Journal Of The American Association For Laboratory Animal Science 2011, 50: 462-5. PMID: 21838972, PMCID: PMC3148637.Peer-Reviewed Original Research
2010
Metachronous Primary Melanoma and Lymphoma
McIntosh BC, Ariyan S, Esche G, Zelterman D, Narayan D. Metachronous Primary Melanoma and Lymphoma. Annals Of Plastic Surgery 2010, 64: 229-232. PMID: 20098111, DOI: 10.1097/sap.0b013e3181a13dbf.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaTumor RegistryYale-New Haven HospitalConnecticut Tumor RegistryEffect of treatmentStudy patientsCutaneous melanomaSurvival differencesPrimary melanomaLymphomaPatientsMelanomaViral inductionDiagnosisGenetic mutationsSurvivalRegistryLonger intervalsMalesGender comparisonsFurther researchImmunosuppressionMalignancyNeoplasmsHospital
2006
Postoperative Radiotherapy for Stage II or III Non–Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results Database
Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative Radiotherapy for Stage II or III Non–Small-Cell Lung Cancer Using the Surveillance, Epidemiology, and End Results Database. Journal Of Clinical Oncology 2006, 24: 2998-3006. PMID: 16769986, DOI: 10.1200/jco.2005.04.6110.Peer-Reviewed Original ResearchConceptsT3-4 tumour stageUse of PORTN2 nodal diseaseEnd Results (SEER) databasePostoperative radiotherapyCell lung cancerLymph nodesNodal diseaseResults databaseTumor stageLung cancerNode stageStage IIHigher American Joint CommitteeAdvanced node stageAmerican Joint CommitteePopulation-based cohortLarger tumor sizeMedian followPerioperative mortalityMale sexTumor sizeSubset analysisCancer stageInclusion criteria
2003
Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary.
Tangir J, Zelterman D, Ma W, Schwartz P. Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstetrics And Gynecology 2003, 101: 251-7. PMID: 12576247, DOI: 10.1016/s0029-7844(02)02508-5.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBiopsy, NeedleChemotherapy, AdjuvantCohort StudiesCombined Modality TherapyFemaleFertilityFollow-Up StudiesGerminomaHumansInfertility, FemaleLogistic ModelsMiddle AgedMinimally Invasive Surgical ProceduresNeoplasm StagingOvarian NeoplasmsOvariectomyPregnancyProbabilityRetrospective StudiesRisk AssessmentSurvival RateTreatment OutcomeConceptsMalignant germ cell tumorsGerm cell tumorsFertility-preserving surgeryCell tumorsFollow-upReproductive functionInternational Federation of Gynecology and Obstetrics (FIGO) stage ITreated with other combinationsStage IIIStage IFIGO stage IFertility-preserving treatmentMedian follow-upLoss of follow-upActinomycin DCase series analysisReproductive function of womenFollow-up informationConservative surgeryNo chemotherapyCongenital anomaliesFunction of womenChemotherapyTumorCisplatin
2002
Statistical Inference for Familial Disease Clusters
Yu C, Zelterman D. Statistical Inference for Familial Disease Clusters. Biometrics 2002, 58: 481-491. PMID: 12229982, DOI: 10.1111/j.0006-341x.2002.00481.x.Peer-Reviewed Original Research
2001
Escaping the stem cell compartment: Sustained UVB exposure allows p53-mutant keratinocytes to colonize adjacent epidermal proliferating units without incurring additional mutations
Zhang W, Remenyik E, Zelterman D, Brash D, Wikonkal N. Escaping the stem cell compartment: Sustained UVB exposure allows p53-mutant keratinocytes to colonize adjacent epidermal proliferating units without incurring additional mutations. Proceedings Of The National Academy Of Sciences Of The United States Of America 2001, 98: 13948-13953. PMID: 11707578, PMCID: PMC61147, DOI: 10.1073/pnas.241353198.Peer-Reviewed Original ResearchThe use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines.
Peng X, Won J, Rutherford T, Fujii T, Zelterman D, Pizzorno G, Sapi E, Leavitt J, Kacinski B, Crystal R, Schwartz P, Deisseroth A. The use of the L-plastin promoter for adenoviral-mediated, tumor-specific gene expression in ovarian and bladder cancer cell lines. Cancer Research 2001, 61: 4405-13. PMID: 11389068.Peer-Reviewed Original ResearchMeSH KeywordsAdenoviridaeAnimalsCytomegalovirusCytosine DeaminaseFemaleFlucytosineFluorouracilGene ExpressionGenetic TherapyGenetic VectorsHumansInhibitory Concentration 50Lac OperonMembrane GlycoproteinsMiceMice, NudeMicrofilament ProteinsNucleoside DeaminasesOvarian NeoplasmsPhosphoproteinsPromoter Regions, GeneticTumor Cells, CulturedUrinary Bladder NeoplasmsXenograft Model Antitumor AssaysConceptsL-plastin promoterBladder cancer cell linesNormal ovarian cellsCancer cell linesOvarian cancer cellsTumor nodulesAdenoviral vectorCell linesNormal peritoneal mesothelial cellsOvarian cellsCD vectorSKOV-3 ovarian cancer cell lineFibroblast cell lineReplication-incompetent adenoviral vectorCancer cellsOvarian cancer cell linesNormal peritoneal cellsPeritoneal mesothelial cellsMouse xenograft modelCytosine deaminase geneSurgical specimensOvarian cancerTumor-specific gene expressionPeritoneal cellsOVCAR-5
1999
Follow‐up recommendations for patients with American Joint Committee on Cancer Stages I–III malignant melanoma
Poo‐Hwu W, Ariyan S, Lamb L, Papac R, Zelterman D, Hu G, Brown J, Fischer D, Bolognia J, Buzaid A. Follow‐up recommendations for patients with American Joint Committee on Cancer Stages I–III malignant melanoma. Cancer 1999, 86: 2252-2258. PMID: 10590365, DOI: 10.1002/(sici)1097-0142(19991201)86:11<2252::aid-cncr12>3.0.co;2-q.Peer-Reviewed Original ResearchConceptsCancer stage IAmerican Joint CommitteePatient education programStage IYale Melanoma UnitSurveillance scheduleSymptomatic recurrenceMelanoma UnitSurveillance examinationsJoint CommitteeOverall survival rateStage of diseaseDetection of recurrenceAsymptomatic recurrenceAsymptomatic patientsDistant recurrenceLocoregional recurrenceHazard ratioDisease recurrenceInitial visitMore recurrencesMost recurrencesLate recurrenceMelanoma patientsRecurrence groupBinary Regression for Risks in Excess of Subject-Specific Thresholds
Zhang H, Zelterman D. Binary Regression for Risks in Excess of Subject-Specific Thresholds. Biometrics 1999, 55: 1247-1251. PMID: 11315077, DOI: 10.1111/j.0006-341x.1999.01247.x.Peer-Reviewed Original ResearchDownregulation of p27KIP1 and Ki67/Mib1 Labeling Index Support the Classification of Thyroid Carcinoma Into Prognostically Relevant Categories
Tallini G, Garcia-Rostan G, Herrero A, Zelterman D, Viale G, Bosari S, Carcangiu M. Downregulation of p27KIP1 and Ki67/Mib1 Labeling Index Support the Classification of Thyroid Carcinoma Into Prognostically Relevant Categories. The American Journal Of Surgical Pathology 1999, 23: 678-685. PMID: 10366150, DOI: 10.1097/00000478-199906000-00007.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, FollicularAdultAgedCarcinoma, PapillaryCell Cycle ProteinsCyclin-Dependent Kinase Inhibitor p27Cyclin-Dependent KinasesDisease-Free SurvivalDown-RegulationFemaleHumansImmunoenzyme TechniquesKi-67 AntigenMaleMicrotubule-Associated ProteinsMiddle AgedPrognosisThyroid NeoplasmsTumor Suppressor ProteinsConceptsKi67/MIB1 labeling indexLow p27Kip1 expressionMIB1 labeling indexThyroid carcinomaFollicular carcinomaP27Kip1 expressionPathologic featuresPrognostic groupsTumor differentiationLabeling indexFavorable pathologic featuresKi67/MIB1Unfavorable pathologic featuresAdverse prognostic factorLarger tumor sizeFollicular cell originDownregulation of p27Kip1Valuable prognostic indicatorCellular proliferationCellular proliferation patternsCyclin-dependent kinase inhibitor p27Kip1High proliferative rateLow p27Kip1Prognostic factorsTumor sizeFunctional activity of murine CD34+and CD34− hematopoietic stem cell populations
Donnelly D, Zelterman D, Sharkis S, Krause D. Functional activity of murine CD34+and CD34− hematopoietic stem cell populations. Experimental Hematology 1999, 27: 788-796. PMID: 10340393, DOI: 10.1016/s0301-472x(99)00032-6.Peer-Reviewed Original ResearchConceptsHematopoietic stem cellsCD34-LinStem cellsMurine bone marrow cellsHematopoietic stem cell populationStem cell populationCD34- hematopoietic stem cellsCompetitive repopulation experimentsHuman hematopoietic stem cellsClinical transplantation protocolsLong-term engraftmentBone marrowMarrow repopulating cellsBone marrow cellsDistinct populationsRepopulation experimentsRepopulating cellsCell populationsBone marrow repopulating cellsCD34 cellsMarrow cellsCell numberCellsFunctional activityBone marrow reconstitutionAssessment of Cardiac and Pulmonary Function in Adult Patients with Hodgkin's Disease Treated with ABVD or MOPP/ABVD Plus Adjuvant Low-Dose Mediastinal Irradiation
Salloum E, Tanoue L, Wackers F, Zelterman D, Hu G, Cooper D. Assessment of Cardiac and Pulmonary Function in Adult Patients with Hodgkin's Disease Treated with ABVD or MOPP/ABVD Plus Adjuvant Low-Dose Mediastinal Irradiation. Cancer Investigation 1999, 17: 171-180. PMID: 10099655, DOI: 10.3109/07357909909021418.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBleomycinCombined Modality TherapyDacarbazineDose-Response Relationship, RadiationDoxorubicinEvaluation Studies as TopicFemaleFollow-Up StudiesHeartHodgkin DiseaseHumansLungMaleMechlorethamineMiddle AgedPhysical ExertionPrednisoneProcarbazineRadiotherapy, AdjuvantRemission InductionRespiratory Function TestsVinblastineVincristineConceptsLeft ventricular ejection fractionMOPP/ABVDHodgkin's diseaseAdult patientsPulmonary functionInvolved-field radiation therapyFEV1/FVC ratioIU/m2Pulmonary function testsVentricular ejection fractionVital capacity valuesTotal lung capacityMediastinal irradiationPulmonary symptomsDiastolic functionModality therapyEjection fractionCardiopulmonary functionFunction testsFVC ratioStudy abnormalitiesCigarette smokersCardiac toxicityLung capacitySuch therapy
1998
Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation
Salloum E, Jillella A, Nadkarni R, Seropian S, Hu G, D'Andrea E, Zelterman D, Cooper D. Assessment of pulmonary and cardiac function after high dose chemotherapy with BEAM and peripheral blood progenitor cell transplantation. Cancer 1998, 82: 1506-1512. PMID: 9554528, DOI: 10.1002/(sici)1097-0142(19980415)82:8<1506::aid-cncr12>3.0.co;2-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarmustineCombined Modality TherapyCytarabineFemaleHeartHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansLungLymphoma, Non-HodgkinMaleMelphalanMiddle AgedNeutropeniaNeutrophilsPodophyllotoxinRespiratory Function TestsRetrospective StudiesVentricular Function, LeftConceptsHigh-dose chemotherapyPulmonary function testsPeripheral blood progenitor cell transplantationBlood progenitor cell transplantationProgenitor cell transplantationPBPC transplantationDose chemotherapyVital capacityCell transplantationAutologous peripheral blood progenitor cell transplantationAbnormal pulmonary function testsVentricular ejection fraction valuesHigh-dose therapyTotal lung capacityTime of reevaluationEjection fraction valuesEquilibrium radionuclide angiographyMediastinal irradiationAdditional therapyComplete remissionDose therapyPulmonary symptomsExpiratory volumePulmonary functionPFT values
1997
A 40-year analysis of 265 gastric carcinoids.
Modlin I, Sandor A, Tang L, Kidd M, Zelterman D. A 40-year analysis of 265 gastric carcinoids. The American Journal Of Gastroenterology 1997, 92: 633-8. PMID: 9128313.Peer-Reviewed Original ResearchConceptsGastric carcinoid tumorsGastric carcinoidsCarcinoid tumorsSurvival rateThird National Cancer SurveyAge-adjusted incidence ratesEnd Results (SEER) databaseNational Cancer SurveyAggressive biological behaviorNational Cancer InstituteEnd Results GroupDistant metastasisGastric malignancyCancer SurveyResults databaseFemale ratioMalignant neoplasmsIncidence rateBenign neoplasmsCarcinoidsCancer InstituteLocalized lesionsCarcinoid casesBiological behaviorWhite femalesGallium scans in the management of patients with Hodgkin's disease: a study of 101 patients.
Salloum E, Brandt D, Caride V, Cornelius E, Zelterman D, Schubert W, Mannino T, Cooper D. Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients. Journal Of Clinical Oncology 1997, 15: 518-27. PMID: 9053473, DOI: 10.1200/jco.1997.15.2.518.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantChildFemaleGallium RadioisotopesHodgkin DiseaseHumansMaleMiddle AgedNeoplasm StagingPredictive Value of TestsRadiotherapy, AdjuvantTomography, Emission-Computed, Single-PhotonTreatment OutcomeConceptsNegative 67Ga scanPositive 67Ga scanTime of diagnosisManagement of patientsHodgkin's diseaseStage IIIStage IPredictive valueGallium scanGross residual diseaseEnd of therapyNegative predictive valueLow predictive valueModality therapyProgressive diseaseResidual diseasePositive scansRadiation therapyPatientsTherapyDiseaseScansTreatmentDiagnosisChemotherapy
1996
Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation.
Salloum E, Doria R, Schubert W, Zelterman D, Holford T, Roberts K, Farber L, Kiehl R, Cardinale J, Cooper D. Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. Journal Of Clinical Oncology 1996, 14: 2435-43. PMID: 8823321, DOI: 10.1200/jco.1996.14.9.2435.Peer-Reviewed Original ResearchConceptsOverall relative riskHodgkin's diseaseRT groupRelative riskSolid tumorsCMT groupRadiation therapyLung cancerBreast cancerEarly-stage Hodgkin's diseaseFull-dose radiation therapyInvolved-field radiationSecond solid tumorsConnecticut Tumor RegistryEarly-stage diseaseLong-term survivorsDifferent therapeutic approachesCases of lungLow-dose radiationSignificant increaseActuarial incidenceMedian followSalvage chemotherapyAdvanced diseaseDurable remissionsTuberculosis in physicians: Compliance with surveillance and treatment
Ramphal-Naley L, Kirkhorn S, Lohman W, Zelterman D. Tuberculosis in physicians: Compliance with surveillance and treatment. American Journal Of Infection Control 1996, 24: 243-253. PMID: 8870908, DOI: 10.1016/s0196-6553(96)90056-5.Peer-Reviewed Original ResearchConceptsPositive skin test resultsSkin test resultsTuberculin skin test resultsPositive Mantoux test resultSkin test conversionMantoux test resultsSkin testingTB surveillanceFull-time physiciansStaff physiciansPoor complianceTest conversionLow prevalenceNegative tuberculin skin test resultsPositive tuberculin skin test resultsHealth AdministrationResident physiciansTuberculin skin test statusAnnual skin testingHalf of physiciansHealth care workersDepartment of PathologyThird of physiciansTuberculosis skin testingOccupational Safety